An Open, Randomized, Multicentre, Phase II Pilot Study
The objective of this study is to evaluate efficacy, safety and quality of life adjuvant docetaxel-cisplatin chemotherapy versus no adjuvant treatment in patients with completely resected NSCLC Stage I-II.
Non-Small Cell Lung Cancer
DRUG: Docetaxel|DRUG: Docetaxel
to compare the effect on disease free survival of adjuvant docetaxel and cisplatin in patients with completely resected stage I-II non-small cell lung cancer versus observation only
to determine the impact on overall survival of adjuvant docetaxel and cisplatin.|to characterise and quantitate toxicity related to this treatment regimen.|to compare quality of life of patients on both treatment arms.
Open multicentre, centrally randomized, two-arm parallel-group, phase II pilot-study. Duration of the Treatment : Arm A - will be 4-6 cycles Docetaxel 75mg/m2 and Cisplatin 75mg/m2 on day 1 every 21 days.

Arm B untreated control group - best supportive care. A follow-up check-up examination will be performed every 3 months for a total of three years.